| Abstract |
Abstract: Objective: To observe the effect of oxiracetam in treatment of cognitive dysfunction after stroke curative effect and adverse reaction. Methods: 100 patients with cognitive impairment after stroke in our hospital were randomly divided into control group (n = 50) and observation group (n = 50). Choose a drug control group piracetam treatment, the observation group of oxiracetam treatment. Before and after treatment, using simple intelligence (MMSE), ability of daily life (ADL), Montreal cognitive assessment scale (MoCA) were evaluated in two groups, by calculating the score rate of change, analysis of the efficiency of treatment, and adverse reactions were observed. Results: after different treatment, the observation group MMSE is better than that of the control group, the difference was statistically significant (P < 0.05); the observation group ADL improvement than the control group, the difference between the two groups was statistically significant (P < 0.05); the observation group MoCA were better than those in the control group, the difference was statistically significant (P < 0.05); the control group and the observation group the incidence of adverse reaction were 12% and 6%, the two groups, but no statistical significance (P>0.05). Conclusion: compared with bared piracetam drugs, drug oxiracetam can significantly improve patients cognitive function, obtain satisfactory curative effect, reduce adverse reactions, is recommended to promote in the clinical application.
|